Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML)
Zeidan A, Qi C, Pandya B, Garnham A, Yang H, Shah M. Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3-Mutated (FLT3 mut+) Acute Myeloid Leukemia (AML). Blood 2019, 134: 3859. DOI: 10.1182/blood-2019-123819.Peer-Reviewed Original ResearchHematopoietic stem cell transplantationEvent-free survivalAcute myeloid leukemiaIncremental cost-effectiveness ratioUS third-party payer perspectiveThird-party payer perspectiveProbabilistic sensitivity analysesSalvage chemotherapyADMIRAL trialOverall survivalEfficacy inputsDeterministic sensitivity analysesIncremental costPayer perspectiveLifetime horizonAllogeneic hematopoietic stem cell transplantationFavorable cost-effectiveness profileHealth statesPost-progression treatmentTerminal care costsTreatment of RelapsedActive treatment optionsEffective therapeutic optionLong-term survivorsTreatment costs